Tobramycin Sulfate

硫酸妥布霉素

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameTobramycin Sulfate
Drug Alias NameTobramycinum硫酸托普霉素硫酸妥布拉霉素tobramicinatobramycine +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsPseudomonas aeruginosa pneumoniaAcute bacterial skin and skin structure infectionsCystic Fibrosis +[10] 
Global Approved IndicationsPseudomonas aeruginosa pneumoniaCystic FibrosisBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1975/06/11
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesViatris Healthcare LtdFresenius Kabi Manufacturing SaHunan Hongchun Pharmaceutical Co Ltd +[4] 
Inactive CompaniesEli Lilly And CompanyPari Pharma Gmbh
Active IndicationsPseudomonas aeruginosa pneumoniaAcute bacterial skin and skin structure infectionsCystic Fibrosis +[9] 
Inactive IndicationsPseudomonas Infections

Other Information

ATC CodeJ01GB01S01AA12
Related LinksWikipediaDrugBankKEGG